Core Viewpoint - The roundtable discussion hosted by Medtronic during the China International Import Expo focused on the clinical application, health economic value, and future development of innovative therapy RDN (Renal Denervation) for the treatment of resistant hypertension in China [1][4]. Group 1: Current Situation of Hypertension in China - The number of hypertension patients in China has reached 245 million, with approximately 8.8% classified as resistant hypertension [2]. - Traditional treatment methods primarily involve medication and lifestyle changes, but long-term adherence is poor, resulting in a blood pressure control rate of less than 30% [2]. - High blood pressure is responsible for about 20% of deaths from chronic diseases globally, and the prevalence of hypertension in China exceeds 20% [2]. Group 2: Challenges in Hypertension Treatment - There are issues with inaccurate diagnosis and significant variability in treatment methods for hypertension [3]. - It is essential to adopt appropriate treatment methods based on individual patient circumstances, especially for resistant hypertension, and to improve treatment quality through new technologies [3]. Group 3: Technological Innovation and RDN - RDN is a minimally invasive therapy that uses radiofrequency energy to block renal sympathetic nerve signals, thereby regulating blood pressure from the source [4]. - The RDN system has been approved for sale in nearly 80 countries globally and is expected to be officially launched in China in 2024 [4]. - The introduction of RDN is seen as a significant upgrade to the hypertension management system, providing new treatment options for doctors and patients [4]. Group 4: Economic and Systemic Considerations - The promotion of RDN therapy should consider long-term social returns rather than just short-term costs, as it can reduce the risk of disabilities and improve quality of life [4]. - Recommendations include establishing financing mechanisms for high treatment costs and incorporating long-term efficacy into assessment standards for reimbursement [4]. Group 5: Importance of Comprehensive Evaluation - The key to the successful implementation of innovative technologies lies in scientific evaluation and the establishment of standardized systems [5]. - A comprehensive evaluation covering the entire patient journey from diagnosis to rehabilitation is advocated, rather than solely focusing on procurement costs [5]. Group 6: Future Perspectives - The emergence of RDN therapy represents a paradigm shift in intervention medicine, moving from merely opening blood vessels to regulating systems [7]. - As clinical understanding of hypertension as a syndrome improves, RDN and similar innovative therapies may provide additional treatment options for resistant hypertension and potentially other diseases [7].